Higher blood levels were linked to a long-term lung disease below 135 nmol/L, but the link disappeared above that level. The study examined Methylmalonic Acid (MMA) in 5,139 adults from a US health survey. The data came from 2013–2014. Researchers looked at chronic obstructive pulmonary disease, or COPD. This is a lasting lung disease that makes breathing harder. The pattern was not a simple “higher means worse” finding. Below 135 nmol/L, higher readings were linked to greater odds of having COPD. Above that point, researchers found no clear link with further increases. The unit nmol/L describes how much of a substance is in blood. Measures of inflammation accounted for 3.7%–10.2% of the link in the analysis. Two measures based on immune cell counts showed the strongest effects. That does not prove inflammation caused the connection. The main pattern also held up across additional checks. This was a snapshot, not a study of future disease. It could not show which came first: changed blood levels or COPD. It also did not test whether lowering those levels improves breathing. The 135 nmol/L point is not a personal target or a disease cutoff. For BioSocial members, this adds context rather than a new score to chase. When sharing your own results, include dates, units, and why testing was done. Comparing notes can help keep a single reading in perspective. Community experiences cannot establish cause, but they can raise useful questions for future studies. What have your readings looked like over time, and what prompted you to track them?